Terveystalo Oy Class A

As of June 30, 2026, Terveystalo Oy Class A carries a market capitalization of 958.68M, placing it among publicly traded companies globally. Its enterprise value stands at 1.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Terveystalo Oy Class A's next confirmed earnings release is scheduled for February 12, 2027.

As of June 30, 2026, Terveystalo Oy Class A has 126.81M shares outstanding.

As of June 30, 2026, Terveystalo Oy Class A trades at a trailing price-to-earnings ratio of 12.94. The price-to-sales ratio is 0.76, and the price-to-book ratio stands at 1.80.

As of June 30, 2026, Terveystalo Oy Class A trades at an EV/EBITDA multiple of 7.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.15 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Terveystalo Oy Class A trades at an EV/FCF ratio of 12.42, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.52B versus a market cap of 958.68M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Terveystalo Oy Class A maintains a current ratio of 0.61, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 121.74, indicating elevated leverage, while an interest coverage ratio of 10.39 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Terveystalo Oy Class A posted a return on equity (ROE) of 13.26, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.83 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.19, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.77, useful for judging operating efficiency across full business cycles. The company generates approximately 146,459.78 in revenue per employee across its workforce of 8,555.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 64.94 indicates how many times Terveystalo Oy Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Terveystalo Oy Class A recorded 19.50M in income tax expense. That works out to an effective tax rate of 20.86, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 93.50M, leaving 74.00M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 6, 2026, Terveystalo Oy Class A's stock has declined approximately 22.63% over the past 52 weeks. The 50-day moving average sits at 7.48, while the 200-day moving average is 8.26.

Over the twelve months ended June 30, 2026, Terveystalo Oy Class A generated 1.25B in revenue and converted that into 74.00M in net income, yielding earnings per share of 0.58. EBITDA reached 216.20M, while operating income came in at 115.60M.

As of June 30, 2026, Terveystalo Oy Class A holds 87.50M in cash and equivalents against 647.40M in total debt, resulting in a net debt position of 366.50M. Total book value stands at 531.80M, with working capital of -142.60M providing operational flexibility.

Terveystalo Oy Class A produced 160.90M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -55.10M in capital expenditures, free cash flow totaled 105.80M - equivalent to 0.84 per share.

Over the twelve months ended June 30, 2026, Terveystalo Oy Class A posted a gross margin of 59.83, reflecting its pricing power and cost economics. The operating margin of 9.23 and net profit margin of 5.91 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Terveystalo Oy Class A paid dividends of 0.80 per share. The dividend payout ratio of 137.03 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 10.96, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 10.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Terveystalo Oy Class A shareholders.

As of June 30, 2026, Terveystalo Oy Class A has an Altman Z-Score of 3.58, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.